{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:43:10Z","timestamp":1791193390848,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,5,12]],"date-time":"2003-05-12T00:00:00Z","timestamp":1052697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1038\/nm875","type":"journal-article","created":{"date-parts":[[2003,5,23]],"date-time":"2003-05-23T14:46:29Z","timestamp":1053701189000},"page":"762-767","source":"Crossref","is-referenced-by-count":354,"title":["Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function"],"prefix":"10.1038","volume":"9","author":[{"given":"Erwan","family":"B\u00e9zard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Leriche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Boraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sokoloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,5,12]]},"reference":[{"key":"BFnm875_CR1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1126\/science.1066969","volume":"294","author":"A Carlsson","year":"2001","unstructured":"Carlsson, A. A paradigm shift in brain research. Science 294, 1021\u20131024 (2001).","journal-title":"Science"},{"key":"BFnm875_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0165-6147(00)01991-X","volume":"23","author":"L Pulverenti","year":"2002","unstructured":"Pulverenti, L. & Koob, G.F. Being partial to psychostimulant addiction therapy. Trends Pharmacol. Sci. 23, 151\u2013153 (2002).","journal-title":"Trends Pharmacol. Sci."},{"issue":"suppl. 1","key":"BFnm875_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.58.suppl_1.S1","volume":"58","author":"P Jenner","year":"2002","unstructured":"Jenner, P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58 (suppl. 1), S1\u2013S8 (2002).","journal-title":"Neurology"},{"key":"BFnm875_CR4","first-page":"309","volume":"75","author":"O Hornykiewicz","year":"1963","unstructured":"Hornykiewicz, O. Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der Substantia nigra des normalen und Parkinson-kranken Menschen. Wien. Klin. Wochenschr. 75, 309\u2013312 (1963).","journal-title":"Wien. Klin. Wochenschr."},{"key":"BFnm875_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/35086062","volume":"2","author":"E Bezard","year":"2001","unstructured":"Bezard, E., Brotchie, J.M. & Gross, C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2, 577\u2013587 (2001).","journal-title":"Nat. Rev. Neurosci."},{"key":"BFnm875_CR6","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1073\/pnas.92.5.1719","volume":"92","author":"D L\u00e9vesque","year":"1995","unstructured":"L\u00e9vesque, D. et al. A paradoxical regulation of the dopamine D3 receptor expression indicates the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. USA 92, 1719\u20131723 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm875_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/35075076","volume":"411","author":"O Guillin","year":"2001","unstructured":"Guillin, O. et al. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411, 86\u201389 (2001).","journal-title":"Nature"},{"key":"BFnm875_CR8","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1073\/pnas.94.7.3363","volume":"94","author":"R Bordet","year":"1997","unstructured":"Bordet, R. et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA 94, 3363\u20133367 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm875_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM196902132800701","volume":"280","author":"GC Cotzias","year":"1969","unstructured":"Cotzias, G.C., Papavasiliou, P.S. & Gellene, R. Modification of Parkinsonism-chronic treatment with L-dopa. New Eng. J. Med. 280, 337\u2013345 (1969).","journal-title":"New Eng. J. Med."},{"key":"BFnm875_CR10","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","volume":"80","author":"RS Burns","year":"1983","unstructured":"Burns, R.S. et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546\u20134550 (1983).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm875_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/mds.870100606","volume":"10","author":"RK Pearce","year":"1995","unstructured":"Pearce, R.K., Jackson, M., Smith, L., Jenner, P. & Marsden, C.D. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov. Disord. 10, 731\u2013740 (1995).","journal-title":"Mov. Disord."},{"key":"BFnm875_CR12","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1046\/j.1460-9568.1998.00264.x","volume":"10","author":"M Morissette","year":"1998","unstructured":"Morissette, M. et al. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 10, 2565\u20132573 (1998).","journal-title":"Eur. J. Neurosci."},{"key":"BFnm875_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0306-4522(00)00130-5","volume":"98","author":"M Quik","year":"2000","unstructured":"Quik, M., Police, S., He, L., Di Monte, D.A. & Langston, J.W. Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98, 263\u2013273 (2000).","journal-title":"Neuroscience"},{"key":"BFnm875_CR14","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/mds.870130506","volume":"13","author":"HL Ryoo","year":"1998","unstructured":"Ryoo, H.L., Pierrotti, D. & Joyce, J.N. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13, 788\u2013797 (1998).","journal-title":"Mov. Disord."},{"key":"BFnm875_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0304-3940(96)12884-6","volume":"214","author":"MJ Hurley","year":"1996","unstructured":"Hurley, M.J., Stubbs, C., Jenner, P. & Marsden, C.A. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci. Lett. 214, 75\u201378 (1996).","journal-title":"Neurosci. Lett."},{"key":"BFnm875_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/22560","volume":"400","author":"M Pilla","year":"1999","unstructured":"Pilla, M. et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400, 371\u2013375 (1999).","journal-title":"Nature"},{"key":"BFnm875_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s002109900167","volume":"361","author":"R Grondin","year":"2000","unstructured":"Grondin, R., Tahar, A.H., Doan, V.D., Ladure, P. & Bedard, P.J. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn-Schmiedebergs Arch. Pharmacol. 361, 181\u2013186 (2000).","journal-title":"Naunyn-Schmiedebergs Arch. Pharmacol."},{"key":"BFnm875_CR18","first-page":"1239","volume":"275","author":"F Sautel","year":"1995","unstructured":"Sautel, F. et al. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 275, 1239\u20131246 (1995).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm875_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/(SICI)1098-2396(199609)24:1<60::AID-SYN7>3.0.CO;2-E","volume":"24","author":"B Levant","year":"1996","unstructured":"Levant, B., Bancroft, G.N. & Selkirk, C.M. In vivo occupancy of D2 dopamine receptors by 7-OH-DPAT. Synapse 24, 60\u201364 (1996).","journal-title":"Synapse"},{"key":"BFnm875_CR20","first-page":"1048","volume":"293","author":"MJ Millan","year":"2000","unstructured":"Millan, M.J. et al. S33084, a novel potent, selective, and competitive antagonist at dopamine D3-receptors: receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293, 1048\u20131062 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm875_CR21","first-page":"1154","volume":"294","author":"C Reavill","year":"2000","unstructured":"Reavill, C. et al. Pharmacological actions of a novel high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 294, 1154\u20131165 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm875_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0922-4106(94)90182-1","volume":"268","author":"C Pilon","year":"1994","unstructured":"Pilon, C. et al. Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur. J. Pharmacol. [Mol. Pharmacol. Sect.] 268, 129\u2013139 (1994).","journal-title":"Eur. J. Pharmacol. [Mol. Pharmacol. Sect.]"},{"key":"BFnm875_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0006-8993(97)01078-0","volume":"779","author":"M Suzuki","year":"1998","unstructured":"Suzuki, M., Hurd, Y.L., Sokoloff, P., Schwartz, J.C. & Sedvall, G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779, 58\u201374 (1998).","journal-title":"Brain Res"},{"key":"BFnm875_CR24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/brain\/124.3.546","volume":"124","author":"T Boraud","year":"2001","unstructured":"Boraud, T., Bezard, E., Bioulac, B. & Gross, C.E. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124, 546\u2013557 (2001).","journal-title":"Brain"},{"key":"BFnm875_CR25","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1073\/pnas.93.5.1945","volume":"93","author":"D Accili","year":"1996","unstructured":"Accili, D. et al. A targeted mutation of the D3 receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. USA 93, 1945\u20131949 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm875_CR26","doi-asserted-by":"crossref","unstructured":"Baik, J.H. et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377, 424\u2013428.","DOI":"10.1038\/377424a0"},{"key":"BFnm875_CR27","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1126\/science.2147780","volume":"250","author":"CR Gerfen","year":"1990","unstructured":"Gerfen, C.R. et al. D1and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429\u20131432 (1990).","journal-title":"Science"},{"key":"BFnm875_CR28","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1002\/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z","volume":"47","author":"O Rascol","year":"2000","unstructured":"Rascol, O. Medical treatment of levodopa-induced dyskinesia. Ann. Neurol. 47, S179\u2013S188 (2000).","journal-title":"Ann. Neurol."},{"key":"BFnm875_CR29","doi-asserted-by":"crossref","unstructured":"Imbert, C., Bezard, E., Guitraud, S., Boraud, T. & Gross, C.E. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J. Neurosci. Meth. 96, 71\u201376.","DOI":"10.1016\/S0165-0270(99)00184-3"},{"key":"BFnm875_CR30","doi-asserted-by":"publisher","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","volume":"21","author":"E Bezard","year":"2001","unstructured":"Bezard, E. et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21, 6853\u20136861 (2001).","journal-title":"J. Neurosci."},{"key":"BFnm875_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/archpsyc.1997.01830150047009","volume":"54","author":"EV Gurevich","year":"1997","unstructured":"Gurevich, E.V. et al. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. Arch. Gen. Psychiatry 54, 225\u2013232 (1997).","journal-title":"Arch. Gen. Psychiatry"},{"key":"BFnm875_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/0922-4106(92)90107-7","volume":"225","author":"P Sokoloff","year":"1992","unstructured":"Sokoloff, P. et al. Pharmacology of human D3 dopamine receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 225, 331\u2013337 (1992).","journal-title":"Eur. J. Pharmacol. Mol. Pharmacol. Sect."},{"key":"BFnm875_CR33","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/sj.bjp.0704192","volume":"133","author":"B Weber","year":"2001","unstructured":"Weber, B., Schlicker, E., Sokoloff, P. & Stark, H. Identification of the dopamine autoreceptor in the guinea-pig retina as D2 receptor using novel subtype-selective antagonists. Br. J. Pharmacol. 133, 1243\u20131248 (2001).","journal-title":"Br. J. Pharmacol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm875","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:34:25Z","timestamp":1684449265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["BFnm875"],"URL":"https:\/\/doi.org\/10.1038\/nm875","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,12]]}}}